1. Home
  2. TURN vs IRD Comparison

TURN vs IRD Comparison

Compare TURN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TURN
  • IRD
  • Stock Information
  • Founded
  • TURN 1981
  • IRD 2018
  • Country
  • TURN United States
  • IRD United States
  • Employees
  • TURN N/A
  • IRD N/A
  • Industry
  • TURN Finance/Investors Services
  • IRD
  • Sector
  • TURN Finance
  • IRD
  • Exchange
  • TURN Nasdaq
  • IRD NYSE
  • Market Cap
  • TURN 35.4M
  • IRD 36.1M
  • IPO Year
  • TURN N/A
  • IRD N/A
  • Fundamental
  • Price
  • TURN $3.95
  • IRD $1.15
  • Analyst Decision
  • TURN
  • IRD Strong Buy
  • Analyst Count
  • TURN 0
  • IRD 1
  • Target Price
  • TURN N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • TURN 45.0K
  • IRD 154.1K
  • Earning Date
  • TURN 02-18-2025
  • IRD 02-19-2025
  • Dividend Yield
  • TURN N/A
  • IRD N/A
  • EPS Growth
  • TURN N/A
  • IRD N/A
  • EPS
  • TURN N/A
  • IRD N/A
  • Revenue
  • TURN $129,297.00
  • IRD $8,381,000.00
  • Revenue This Year
  • TURN N/A
  • IRD N/A
  • Revenue Next Year
  • TURN N/A
  • IRD $29.37
  • P/E Ratio
  • TURN N/A
  • IRD N/A
  • Revenue Growth
  • TURN 6.32
  • IRD N/A
  • 52 Week Low
  • TURN $3.12
  • IRD $0.81
  • 52 Week High
  • TURN $4.47
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • TURN 61.40
  • IRD N/A
  • Support Level
  • TURN $3.78
  • IRD N/A
  • Resistance Level
  • TURN $4.04
  • IRD N/A
  • Average True Range (ATR)
  • TURN 0.15
  • IRD 0.00
  • MACD
  • TURN 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • TURN 80.43
  • IRD 0.00

About TURN 180 Degree Capital Corp.

180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: